A Troubling Reality for CRC Survivors: The Polypharmacy Dilemma
The Issue:
Polypharmacy, the use of multiple medications simultaneously, is a growing concern for colorectal cancer (CRC) survivors in Australia. New research reveals a startling rate of polypharmacy among this population, raising questions about the long-term impact on their health and quality of life.
But here's where it gets controversial...
While polypharmacy is often associated with increased risks and adverse events, especially during active cancer treatment, the focus on post-treatment survivors has been limited. This study aims to shed light on a critical gap in our understanding of CRC survivorship.
Research Findings:
The Australian research team conducted a comprehensive study, tracking medicine use in CRC patients from the year before their diagnosis up to five years post-diagnosis. The results were eye-opening:
- Over 70% of CRC patients experienced polypharmacy at some point during the study period, with almost 50% continuing to do so in the years two to five post-diagnosis.
- The number of medications increased significantly in the first year after diagnosis, with a notable rise in analgesics and psychotropic medications.
- Polypharmacy was more common in females, older individuals (aged 75+), those with comorbidities, and residents of socioeconomically disadvantaged areas.
Data Sources:
The researchers utilized the Medicines Intelligence Data Platform, a powerful tool that linked electronic health records with various data sources, including the Pharmaceutical Benefits Scheme, hospital admissions, cancer registries, and death records. This comprehensive approach allowed for a detailed analysis of medicine use and its impact on CRC survivors.
Survival Rates and Polypharmacy:
Interestingly, the study found similar polypharmacy rates across different cancer stages, with 74% in the localized group, 79% in the regional group, and 79% in the metastatic group experiencing polypharmacy at some point. However, survival rates varied significantly, with higher survival in localized and regional disease (87% and 78%, respectively) compared to metastatic disease (27%).
The Composition of Medications:
The study also revealed changes in the types of medications dispensed post-diagnosis. Antiemetics, painkillers, and antidepressants saw increased usage, reflecting the need for supportive care during and after treatment. Notably, opioids, other analgesics, and antidepressants remained the most commonly dispensed medications throughout the post-active treatment period.
Implications for CRC Survivors:
The researchers emphasize the importance of addressing the unique challenges faced by CRC survivors, such as ongoing neuropathy, pain, and psychological symptoms. They argue that quality survivorship care should prioritize the prevention and management of non-cancer comorbidities to improve the overall health and well-being of these individuals.
And this is the part most people miss...
Polypharmacy in CRC survivors treated with curative intent is particularly concerning. It indicates excess morbidity and a lower quality of life for individuals who have overcome cancer but continue to face health challenges. This highlights the need for tailored interventions and ongoing support to ensure these survivors can lead healthy and fulfilling lives.
Thoughts and Questions:
- How can we better support CRC survivors to manage their medication regimens and improve their overall health?
- Are there alternative approaches to managing pain and psychological symptoms that could reduce the reliance on polypharmacy?
- What role do socioeconomic factors play in the prevalence of polypharmacy among CRC survivors?
Feel free to share your thoughts and experiences in the comments! Let's spark a conversation to raise awareness and find solutions for this critical issue.
